Agile Therapeutics (NASDAQ:AGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note published on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Price Performance

Shares of AGRX opened at $1.47 on Friday. The company’s 50-day moving average is $0.96 and its 200-day moving average is $0.82. Agile Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $2.88.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter. The company had revenue of $5.72 million for the quarter.

Institutional Investors Weigh In On Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC increased its holdings in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the period. Armistice Capital LLC owned about 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. 10.92% of the stock is currently owned by institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.